Veterinary journal (London, England : 1997) · 2026
Development and validation of an indirect ELISA based on recombinant N-P fusion protein for detecting antibodies against parrot bornavirus in psittacine birds.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suksai Parut, Jala Siriluk, Meetipit Phawaran, Kongmakee Piyaporn, Lertwatcharasarakul Preeda
Аннотация
Parrot bornavirus (PaBV) is a significant pathogen of psittacine birds and the etiological agent of proventricular dilatation disease (PDD). Although asymptomatic infections are common, clinical presentation is variable, posing substantial challenges for diagnosis and disease control. This study developed and validated an indirect enzyme-linked immunosorbent assay (iELISA) based on recombinant nucleoprotein (N), phosphoprotein (P), and an N-P fusion protein derived from PaBV-4 for the serological detection of PaBV-specific antibodies in psittacine birds. Immunodominant, hydrophilic regions were identified using in silico epitope prediction and antigenicity scoring. Recombinant proteins were expressed, purified, and confirmed via Western blot to exhibit specific reactivity with PaBV-positive sera. The N-P fusion protein (48 kDa) demonstrated the highest signal intensity and sensitivity. The optimized iELISA showed 92.9% sensitivity and 96.7% specificity at a sample-to-positive (S/P) ratio cut-off of 0.2064, and no antibody cross-reactivity with other avian pathogens was detected. Receiver operating characteristic (ROC) curve analysis yielded an area under the curve (AUC) of 0.985, indicating excellent diagnostic accuracy. Testing 208 serum samples from captive psittacine birds in Thailand revealed a PaBV seroprevalence of 68.27%, suggesting widespread subclinical infection. The developed iELISA represents a reliable and practical tool for PaBV serological surveillance and may serve as a valuable complement to molecular diagnostic methods for improved disease monitoring and control.